MED

Medifast, Inc. (MED) Risks & Opportunities Analysis (2026)

Invetso Score: 5/10 — Balanced · Last Updated: 2026-09-01

Overall Score

Valuation

Trading at a very low EV/Sales multiple of 0.30x and P/S of 0.44x, suggesting the market is pricing in limited growth.

Price-to-book of 0.72x and price-to-fair-value of 0.72x indicate the shares remain below stated book/fair value measures.

Profitability

TTM margins remain negative, with EBIT margin at -4.4% and net margin at -8.1%.

Returns are still depressed, with ROA at -9.8%, ROE at -12.7%, and ROIC at -7.7%.

Liquidity Balance Sheet

Current ratio of 4.86x and quick ratio of 4.35x indicate strong short-term liquidity.

Debt-to-equity of 0.14x and debt-to-assets of 0.11x suggest leverage remains modest despite negative EBITDA.

Cash Flow

Operating cash flow remains positive, but free cash flow conversion is modest with FCF/OCF at 45.6%.

FCF yield is only 2.8% and price-to-free-cash-flow is elevated at 35.1x, limiting cash-flow-based upside.

Operational Efficiency

Gross margin is healthy at 69.2%, but SG&A consumes 75.4% of revenue, pressuring operating profitability.

Inventory turnover of 4.6x and a negative cash conversion cycle of -57.0 days show decent working-capital management.

Sources

  • Company filings (10-K, 10-Q, investor presentations)
  • Financial and market data providers
  • Public news and industry information

🔒 Go Beyond This Framework

This is one of 10 institutional-grade frameworks Invetso runs on Medifast, Inc.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

Create your free account on Invetso →